Cor Therapeutics
Executive Summary
Nets $49.1 mil. in proceeds from public offering of 3.45 mil. shares of newly issued common stock, South San Francisco cardiovascular disease R&D firm announces Oct. 28. The offering included 450,000 shares exercised in an over-allotment by underwriters Robertson, Stephens and Montgomery Securities.